Schwarz Pharma wins OK for Parkinson's patch

As expected, Germany's Schwarz Pharma won FDA approval to market its Neupro patch for Parkinson's disease. "Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease," said the FDA in a statement. The patch delivers the therapy rotigotine for the brain disease. Rotigotine is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning. The system is applied to the skin once a day and provides rotigotine continuously to the body for 24 hours.

- check out the release for more information

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.